Novartis (SWX:NOVN) Puts Remibrutinib In Focus As Its Undervalued Case Holds

Novartis (SWX:NOVN) just put fresh data on the table. Its oral BTK inhibitor remibrutinib hit all primary and key secondary endpoints in two Phase III multiple sclerosis trials, with preliminary results showing a favorable safety profile.

For context, Novartis shares trade at CHF120.92, with the 7-day share price return up 3.83% while the 30-day and 90-day share price returns are down 2.28% and 3.26% respectively. However, the 1-year total shareholder return of 24.45% and 5-year total shareholder return of 101.93% point to stronger momentum over longer horizons, which recent BTK and Cosentyx updates may be helping to support.

Scan how Novartis fits alongside other large healthcare players by comparing it with a curated group of list of solid balance sheet and fundamentals (204 results) that aim to pair resilience with consistent fundamentals.

Recent gains now sit against a softer 1 to 3 month stretch for Novartis. Are you seeing a durable read on the underlying business, or a sentiment swing that the current valuation already captures?

Most Popular Narrative: 4% Undervalued

On the most followed narrative, Novartis screens as modestly undervalued, with a fair value of CHF126.13 against the last close of CHF120.92. This frames the recent BTK data in the context of a slightly conservative market stance.

Operational efficiency gains from portfolio streamlining (e.g. previous spin-offs and exiting non-core lines) and productivity improvements are driving core margin expansion and higher free cash flow. This can be reinvested in R&D and shareholder returns, supporting long-term earnings and net margin growth.

The announced $10 billion share buyback program, in addition to a strong dividend and significant free cash flow, enhances potential EPS growth and return on equity. This could result in rerating of the stock as medium-term demand and profitability tailwinds materialize.

See why 109 investors see Novartis as 4% undervalued.

Result: Fair Value of CHF126.13 (UNDERVALUED)

Still, the narrative can unravel if loss of exclusivity on key therapies or tighter global pricing pressure ends up biting harder than analysts currently factor in.

Find out about the key risks to this Novartis narrative.

Next Steps

Sentiment around Novartis is split, with solid long-term returns on one side and real uncertainties on the other. Move quickly and check the full picture yourself. To weigh up both sides of the argument in one place, review the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Novartis?

If you stop with Novartis, you risk missing other opportunities that match your style. Use the screener to widen your field without losing discipline.

• Target long-term compounding potential by scanning companies that combine earnings power with appealing valuations through the 202 high quality undervalued stocks.
• Strengthen your income stream by reviewing businesses that aim to support higher yields and consistent payouts using the 164 dividend fortresses.
• Reduce portfolio stress by focusing on financially robust candidates surfaced in the 225 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com